Impact of increasing CD4 count threshold eligibility for antiretroviral therapy initiation on advanced HIV disease and tuberculosis prevalence and incidence in South Africa
An interrupted time series analysis
Bibliographic Data
INTRODUCTION: We investigated the impact of increasing CD4 count eligibility for antiretroviral therapy (ART) initiation on advanced HIV disease (AHD) and tuberculosis (TB) prevalence and incidence among people living with HIV (PLHIV) in South Africa. METHODS: We conducted an interrupted time series analysis with de-identified data of PLHIV aged ≥15 years initiating ART between April 2012 and February 2020 at 65 primary healthcare clinics in KwaZulu-Natal, South Africa. Outcomes included monthly proportions of new ART initiators presenting with AHD (CD4 count <200 cells/μL) and TB disease. We created a cohort of monthly ART initiators without TB and evaluated the cumulative incidence of TB within 12 months follow-up. We used segmented binomial regression models to estimate relative risks (RR) of outcomes, allowing for a step and slope change after expanding the ART initiation CD4 count eligibility from <350 to <500 cells/μL in January 2015 and following Universal Test and Treat (UTT) implementation in September 2016. RESULTS: Among 209 984 participants, median age was 32 (range: 26-38), and 141 499 (67.4%) were female. After January 2015, the risk of AHD at initiation decreased in step by 25.0% (RR=0.750, 95% CI 0.688 to 0.812) and further reduced by 26.9% following UTT implementation (RR=0.731, 95% CI 0.681 to 0.781). The risk of TB at initiation also decreased in step by 27.6% after January 2015 (RR=0.724, 95% CI 0.651 to 0.797) and further decreased by 17.4% after UTT implementation (RR=0.826, 95% CI 0.711 to 0.941) but remained stable among initiators with AHD. Among the incidence cohort, we saw a step decrease in the risk of new TB by 31.4% (RR=0.686, 95% CI 0.465 to 0.907) following UTT implementation. Among the incidence cohort with AHD, there was weak evidence of a step decrease in the risk of new TB (RR=0.755, 95% CI 0.489 to 1.021), but the slope decreased by 9.7% per month (RR=0.903, 95% CI 0.872 to 0.934) following UTT implementation. CONCLUSIONS: Our data support the added benefit of decreased TB co-burden with expanded ART access. Early diagnosis and immediate linkage to care should be prioritised among PLHIV
Antiretroviral therapy · Cohort · Cohort study · Confidence interval · Cumulative incidence · Interrupted time series · Psychological intervention · Relative risk · Tuberculosis · Viral load · Demography · HIV/AIDS drug development and treatment · HIV/AIDS Research and Interventions · Medicine · Tuberculosis Research and Epidemiology · Immunology · Internal Medicine · Pediatrics
Advanced HIV disease among newly diagnosed clients identified through community- and facility-based HIV testing services in Eswatini
Quality assessment of data for decentralised antiretroviral therapy referrals and laboratory results in the South African national electronic HIV management register Tier.Net
The impact of the Covid-19 lockdown on HIV care in 65 South African primary care clinics
Interrupted time series regression for the evaluation of public health interventions
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
Misreporting of Patient Outcomes in the South African National HIV Treatment Database
Progress towards the Unaids 90–90-90 goals by age and gender in a rural area of KwaZulu-Natal, South Africa
Understanding the effects of universal test and treat on longitudinal HIV care outcomes among South African youth
Attrition from Care Among Men Initiating ART in Male-Only Clinics Compared with Men in General Primary Healthcare Clinics in Khayelitsha, South Africa
The health impact of free access to antiretroviral therapy in South Africa
| Unique citing works | 2 |
|---|---|
| Citations per year | 2 |
| Citation span | 2026 - 2026 (1) |
| Citation velocity | current |
| Highly cited | No |
| Citation types | Neutral: 2 |